Douglas Dahl, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Civco
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (General Urology)
    Ineligible company:
    Vertex
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (General Urology)
    Ineligible company:
    Tak Pharmaceuticals
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Oncology)
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    Bristol Myers Squibb
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    Eli Lilly
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    GlaxoSmithKline
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    Abbvie
    Date added:
    Date updated:
    01/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    Johnson and Johnson
    Date added:
    Date updated:
    01/27/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer